migraine
Conditions
Interventions
Control group:Oral Nimodipine tablets (Bayer Healthcare Co., LTD., SinopOD H20003010), 30 mg 3 times a day for 4 weeks.
Experiment group one:rTMS treatment: The MagTD 40 transcranial magnetic stimulation therapy instrument was used, and the fig-8 coil was placed on the primary motor cortex (M1 region) on the healthy si
The treatment was performed 4 times a week for 4 weeks, and the efficacy was evaluated at 2 weeks and 4 weeks after the start of treatment. During this time, the patient is observed and asked for any
Experiment group two:The resistance training program was carried out for 4 weeks, 4 times a week, 45 to 60 min each time (including 5 min jogging warm-up and 5 min relaxation stretching), with the ini
? left and right lateral flexion
? posterior extension
? Rotate left and right
? Neutral position.
(2) Resistance training of upper limb muscle group: seated chest push, seated row, elbow flexion, side lift.
(3) Lower limb muscle resistance training: squat, hip abduction, hip ex
Sponsors
Hospital of Southwest University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Meet the diagnostic criteria for migraine in the third edition of the International Classification of Headache Disorders (ICHD) published by the International Headache Association. (2) no migraine related treatment other than oral analgesics has been received within one month prior to starting treatment. (3) Age 18-60 years old. (4) Have received primary education. (5) Patients voluntarily joined the study, had good compliance, cooperative ability, and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Headache caused by other diseases or drug abuse. (2) The patient has an acute or uncontrollable seizure disease, a history of craniocerebral trauma, severe organ insufficiency, malignant tumor, seizure or convulsive seizure history, etc. (3) There are contraindications for transcranial magnetic stimulation therapy: scalp damage or infection; A metal stent, electronic device or other magnetic object implanted in the skull or body cavity; History of adverse reactions to magnetic therapy. (4) There is visual or hearing impairment, communication impairment, unable to complete the test. (5) Patients with cognitive dysfunction. (6) Primary depression and anxiety disorder. (7) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Migraine symptom grading Scale;Efficacy evaluation;Hamilton Anxiety Scale;Pittsburgh Sleep Quality Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale; | — |
Countries
China
Contacts
Public ContactYuwei Wu
School of Physical Education, Southwest University
Outcome results
None listed